Exelixis Balance Sheet
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis financial position
At the end of fiscal 2025, Exelixis reported total assets of $2.84 billion, down 3.5% from a year earlier against total liabilities of $683.1 million. Shareholders' equity stood at $2.16 billion, or 76.0% of assets. The company held $482.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.56, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis balance sheet (annual)
| Fiscal year (USD) | FY 20252026-01-02 | FY 20242025-01-03 | FY 20232023-12-29 | FY 20222022-12-30 | FY 20212021-12-31 | FY 20202021-01-01 | FY 20192020-01-03 | FY 20182018-12-28 | FY 20172017-12-29 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 482.49M | 217.37M | 262.99M | 501.19M | 647.17M | 319.22M | 266.50M | 314.77M | 183.16M | 151.69M |
| Short-Term Investments | 576.60M | 893.90M | 732.31M | 807.27M | 819.90M | 887.32M | 585.74M | 378.56M | 204.61M | 268.12M |
| Receivables | 286.92M | 265.44M | 237.41M | 214.78M | 282.65M | 160.88M | 119.07M | 162.77M | 77.30M | 40.44M |
| Inventory | 21.69M | 22.39M | 17.32M | 33.30M | 27.49M | 20.97M | 12.89M | 9.84M | 6.66M | 3.34M |
| Total Current Assets | 1.44B | 1.47B | 1.32B | 1.62B | 1.83B | 1.45B | 1.01B | 897.02M | 484.87M | 469.00M |
| Property, Plant & Equipment | 98.96M | 119.39M | 128.73M | 110.62M | 104.03M | 67.38M | 48.89M | 50.90M | 25.74M | 2.07M |
| Goodwill | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
| Long-Term Investments | 603.60M | 637.29M | 728.72M | 756.73M | 371.11M | 330.75M | 536.38M | 158.29M | 64.25M | 55.60M |
| Total Assets | 2.84B | 2.95B | 2.94B | 3.07B | 2.62B | 2.14B | 1.89B | 1.42B | 655.29M | 595.74M |
| Accounts Payable | 29.62M | 38.19M | 33.77M | 32.67M | 24.26M | 23.63M | 11.58M | 10.90M | 9.57M | 6.57M |
| Short-Term Debt | — | — | — | — | — | — | — | — | — | 189.12M |
| Total Current Liabilities | 405.64M | 403.77M | 394.28M | 324.36M | 337.59M | 204.66M | 142.75M | 105.47M | 115.17M | 268.79M |
| Long-Term Debt | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Liabilities | 683.10M | 703.49M | 678.45M | 583.06M | 405.62M | 258.22M | 199.70M | 134.83M | 370.33M | 506.42M |
| Shareholders' Equity | 2.16B | 2.24B | 2.26B | 2.49B | 2.21B | 1.88B | 1.69B | 1.29B | 284.96M | 89.32M |
| Retained Earnings | -76.83M | -98.65M | -173.35M | -34.23M | -216.51M | -447.57M | -559.35M | -880.36M | -1.83B | -1.98B |
| Total Debt | — | — | — | — | — | — | — | — | 0 | 189.12M |
| Net Cash (Debt) | 1.06B | 1.11B | 995.30M | 1.31B | 1.47B | 1.21B | 852.24M | 693.33M | 387.77M | 230.68M |
| Shares Outstanding | 262.48M | 281.73M | 302.79M | 323.95M | 318.84M | 311.63M | 304.83M | 299.88M | 296.21M | 289.92M |
This table shows 10 annual periods of Exelixis's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a balance sheet?